Advantage Alpha Capital Partners LP Acquires 3,017 Shares of Enovis Co. (NYSE:ENOV)

Advantage Alpha Capital Partners LP boosted its holdings in Enovis Co. (NYSE:ENOV) by 3.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 90,972 shares of the company’s stock after purchasing an additional 3,017 shares during the period. Advantage Alpha Capital Partners LP owned approximately 0.16% of Enovis worth $3,992,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ENOV. UMB Bank n.a. increased its holdings in shares of Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after buying an additional 437 shares during the period. Pinnacle Bancorp Inc. increased its stake in Enovis by 54.5% in the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after purchasing an additional 300 shares during the period. FMR LLC lifted its position in Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after purchasing an additional 484 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Enovis during the third quarter valued at approximately $217,000. Finally, Legacy Capital Wealth Partners LLC bought a new position in shares of Enovis in the fourth quarter worth approximately $228,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC dropped their price target on shares of Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a research report on Thursday, February 27th.

Enovis Price Performance

Shares of Enovis stock opened at $39.12 on Monday. The company has a market cap of $2.23 billion, a PE ratio of -17.86 and a beta of 2.05. The business has a 50 day moving average of $42.72 and a 200 day moving average of $43.50. Enovis Co. has a 52 week low of $35.14 and a 52 week high of $62.79. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV) last announced its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.14 million. As a group, equities research analysts forecast that Enovis Co. will post 2.79 earnings per share for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.